3 patents currently held
7 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Sep 2038. from the record
Of the 7 now held by other companies, 7 name Pharmabiome AG as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Sep 2038
Next term end
2
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends no later than Sep 2038 · Medium confidence
Also notable
Ends Nov 2038 · High confidence
Bacterial Extracellular Vesicles
US 11,524,037
Cited by 6 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2038. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Compositions and Methods for Treating Disease Using a Blautia Strain
US 10,493,113
The most cited patent in this portfolio, cited by 12 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2038.
Formerly held, still cited
Notable
Ends Nov 2035 · High confidence
Cited by 168 later US patents, top 5% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
now held by Pharmabiome AG
Also notable
Ends Nov 2035 · Medium confidence
Cited by 112 later US patents, top 5% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
now held by Pharmabiome AG
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jun 3, 2027The maintenance fee for Compositions and Methods for Treating Disease Using a Blautia Strain (US 10,493,113) comes due Jun 3, 2027. Unpaid by Dec 3, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Bacterial Extracellular Vesicles | 2 in force | to Sep 2038 |
| Compositions and Methods for Treating Disease Using a Blautia Strain | 1 in force | to Nov 2038 |
Patents held now
Soonest term end first.
Showing 1 to 3 of 3
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,524,037 | Bacterial Extracellular Vesicles In force · Medium confidence | In force | Medium confidence | |
| US 12,109,243 | Bacterial Extracellular Vesicles In force · Medium confidence | In force | Medium confidence | |
| US 10,493,113 | Compositions and Methods for Treating Disease Using a Blautia Strain In force · High confidence | In force | High confidence |
Also on record, not counted in the 3: 7 patents in force now held by others · 6 patents ended · 3 applications pending · 35 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
2 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed